Network Pharmacology-Based Prediction of Anticancer Targets of Mebendazole: Integrating Molecular Targets, Signaling Pathways, and Clinical Evidence

Cancer remains one of the most formidable challenges in modern medicine, with millions of new cases diagnosed globally each year. While researchers constantly seek new drugs to fight these diseases, a different strategy has gained traction: finding new uses for medicines that are already approved and safe for other conditions. This approach, known as drug repurposing, allows scientists to bypass years of safety testing and move more quickly toward helping patients. One such candidate is mebendazole, a medication that has been used for decades to treat intestinal worm infections. Its primary job is to stop parasites from dividing by interfering with the tiny structural fibers inside their cells. Because human cells use similar fibers to divide, scientists have long suspected that mebendazole might also disrupt the uncontrolled growth of cancer cells. However, cancer is a complex disease driven by many different biological pathways, and it has remained unclear exactly how this simple, inexpensive drug might work against such a diverse enemy.

A recent study by researchers at the Birla Institute of Technology and Science and Govindrao Wanjari College of Technology in India set out to map the full scope of mebendazole's potential against cancer. Instead of testing the drug on just one type of cell, the team used a computational method called network pharmacology. This approach acts like a massive digital map, connecting a drug to the many proteins it might touch, and then tracing how those proteins interact with one another to influence disease. By feeding the chemical structure of mebendazole into powerful databases, the researchers predicted which human proteins the drug would likely bind to, and then cross-referenced those predictions with known cancer genes. They filtered the results to find the most reliable connections, creating a focused list of targets that the drug could hit to stop tumor growth.

The analysis revealed that mebendazole is not a single-target weapon but a multi-pronged attacker. The study identified fourteen high-confidence targets, with the most significant being proteins involved in cell structure, blood vessel growth, and cell signaling. The primary target remains the structural fiber known as beta-tubulin, which the drug disrupts to prevent cells from dividing. However, the study showed that mebendazole also targets a protein called VEGFR2, which acts as a switch for growing new blood vessels that feed tumors. By blocking this switch, the drug can starve a tumor of its supply line. Furthermore, the researchers found that mebendazole interferes with the BRAF protein and a pathway involving TNIK, both of which are critical drivers of cancer cell proliferation in specific types of tumors. The drug also appears to influence proteins that control whether a cell lives or dies, effectively pushing cancer cells toward self-destruction.

To understand how these individual targets work together, the researchers built a network diagram showing how the proteins interact. In this web of connections, a few key proteins emerged as central hubs. Beta-tubulin, VEGFR2, BRAF, and a protein called p53 were found to be the most connected nodes, suggesting that when mebendazole hits these points, it sends ripples through the entire system, disrupting multiple cancer processes at once. The study confirmed that these targets are linked to major biological pathways, including those that regulate cell division, cell death, and the signals that tell cells to grow. This multi-target action is significant because it means the cancer would have to develop resistance to several different mechanisms simultaneously to survive, making it harder for the disease to outsmart the treatment.

The researchers did not stop at computer models; they checked their findings against real-world data from clinical trials and published case reports. They found that the predictions matched what has been observed in patients with specific cancers. For instance, in trials involving glioblastoma, an aggressive brain tumor, the drug showed promise when combined with standard radiation and chemotherapy, with evidence suggesting it could penetrate the brain's protective barrier. In colorectal cancer, a trial combining mebendazole with standard chemotherapy drugs resulted in significant tumor shrinkage compared to a placebo. A notable case report described a patient with metastatic colorectal cancer who experienced near-complete remission of their lung and lymph node metastases after taking the drug. These real-world outcomes align with the computer predictions, particularly regarding the drug's ability to block blood vessel growth and interfere with the Wnt signaling pathway, which is often overactive in colorectal cancer.

Despite these encouraging signs, the study also highlighted a major hurdle that has slowed the drug's progress in cancer care. The primary obstacle is not the drug's ability to kill cancer cells, but the difficulty of getting enough of it into the bloodstream. Mebendazole is poorly absorbed by the human body when taken as a standard pill, meaning that even if the dose is high, the amount reaching the tumor is often too low to be effective. This issue caused one clinical trial to be stopped early because researchers could not achieve the necessary concentration of the drug in the patients' blood. The authors suggest that this barrier is solvable through new formulation technologies, such as packaging the drug in nanoparticles or mixing it with high-fat meals to boost absorption, rather than changing the drug itself.

The study concludes that mebendazole is a genuine multi-target anticancer agent with a solid biological basis for its activity. By disrupting cell structure, blocking blood vessel growth, and interfering with key signaling pathways, it attacks cancer from several angles at once. While the drug has shown efficacy in brain and colorectal cancers in early trials, the path forward requires solving the absorption problem to ensure patients receive a therapeutic dose. The researchers propose that with better delivery methods, mebendazole could be prioritized for further clinical testing in glioblastoma, colorectal cancer, and non-small cell lung cancer. This work provides a clear molecular roadmap for why this old worm medication might become a new weapon against cancer, offering a potential, accessible, and affordable option for patients if the delivery challenges can be overcome.